Stockreport

KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024

KalVista Pharmaceuticals, Inc.  (KALV) 
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.kalvista.com
PDF – US subgroup in the phase 3 KONFIDENT trial demonstrates median time to treatment of 38 minutes and time to beginning of symptom relief 1.3 hours –– Despite growing use [Read more]